Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma

Published:2016-08-11 Issue:10 Volume:18 Page:1434-1441
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:NEUONC

Author:

Wick Wolfgang,Chinot Olivier L.,Bendszus Martin,Mason Warren,Henriksson Roger,Saran Frank,Nishikawa Ryo,Revil Cedric,Kerloeguen Yannick,Cloughesy Timothy

Funder

F. Hoffmann-La Roche Ltd

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Clinical Neurology,Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/18/10/1434/17430910/now091.pdf

Reference29 articles.

1. Central Brain Tumor Registry of the United States. Available at http://www.cbtrus.org/ . Accessed November 25, 2015.

2. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

3. Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

4. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

5. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis;Neurosurgical Review;2024-08-20

2. Imaging timing after surgery for glioblastoma: an evaluation of practice in Great Britain and Ireland (INTERVAL-GB)- a multi-centre, cohort study;Journal of Neuro-Oncology;2024-08-06

3. Radiation-Induced Cerebral Contrast Enhancements Strongly Share Ischemic Stroke Risk Factors;International Journal of Radiation Oncology*Biology*Physics;2024-04

4. Glioblastoma Therapy: Past, Present and Future;International Journal of Molecular Sciences;2024-02-21

5. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma;Clinical Cancer Research;2024-01-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3